PMID- 23462218
OWN - NLM
STAT- MEDLINE
DCOM- 20140110
LR  - 20130627
IS  - 1473-5571 (Electronic)
IS  - 0269-9370 (Linking)
VI  - 27
IP  - 11
DP  - 2013 Jul 17
TI  - MHC-driven HIV-1 control on the long run is not systematically determined at 
      early times post-HIV-1 infection.
PG  - 1707-16
LID - 10.1097/QAD.0b013e328360a4bd [doi]
AB  - INTRODUCTION: Human leukocyte antigen (HLA) class I-driven long-term protection 
      against HIV-1 is mainly associated with HLA-B*27 and HLA-B*57. This effect is 
      observed early after infection. Clarification needs to be established concerning 
      the moment of action for the other HLA-B or HLA-C alleles. METHODS: HLA-B and 
      HLA-C alleles from 111 individuals that control HIV-1 disease for over 8 years 
      and from 747 seroconverters frequencies were compared. Also, HLA-B and HLA-C 
      influence on early levels of plasma HIV-RNA, cellular HIV-DNA, CD4, CD8 and 
      CD4/CD8 ratio was evaluated among the seroconverters. We performed univariate, 
      multivariate and haplotypic analyses in order to disentangle the respective 
      contribution of the HLA-B and HLA-C genes. RESULTS: The haplotypes analysis shows 
      three patterns of protective effects of HLA-B and HLA-C alleles or haplotypes. 
      First, the HLA B*57, HLA-B*27, HLA-B*13 and HLA-C*14 alleles, which have a strong 
      effect on long-term disease control, also influence at least one of the early 
      infection phenotypes. Second, HLA-B*52 has a strong effect during early time 
      points on HIV-RNA without significant effect on the long-term control of HIV-1. 
      Finally, the HLA-B*14-C*08 haplotype has a strong effect on the long-term 
      protection, without influencing early viral control. CONCLUSION: Our study 
      highlighted independent effects of HLA-B and HLA-C alleles on HIV-disease 
      progression. Furthermore, some alleles appeared to be specifically associated 
      with either long-term control or early virological parameters, suggesting 
      different immunological mechanisms according to the disease stages.
FAU - Antoni, Guillemette
AU  - Antoni G
AD  - Epidemiology and Public Health Service, APHP, Hopital du Kremlin Bicetre, 
      Universite Paris-Sud, Paris, France.
FAU - Guergnon, Julien
AU  - Guergnon J
FAU - Meaudre, Celine
AU  - Meaudre C
FAU - Samri, Assia
AU  - Samri A
FAU - Boufassa, Faroudy
AU  - Boufassa F
FAU - Goujard, Cecile
AU  - Goujard C
FAU - Lambotte, Olivier
AU  - Lambotte O
FAU - Autran, Brigitte
AU  - Autran B
FAU - Rouzioux, Christine
AU  - Rouzioux C
FAU - Costagliola, Dominique
AU  - Costagliola D
FAU - Meyer, Laurence
AU  - Meyer L
FAU - Theodorou, Ioannis
AU  - Theodorou I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
SB  - IM
MH  - Gene Frequency
MH  - *Genetic Predisposition to Disease
MH  - HIV Infections/*immunology
MH  - HIV-1/*immunology
MH  - HLA-B Antigens/*genetics/*immunology
MH  - HLA-C Antigens/*genetics/*immunology
MH  - Haplotypes
MH  - Humans
EDAT- 2013/03/07 06:00
MHDA- 2014/01/11 06:00
CRDT- 2013/03/07 06:00
PHST- 2013/03/07 06:00 [entrez]
PHST- 2013/03/07 06:00 [pubmed]
PHST- 2014/01/11 06:00 [medline]
AID - 10.1097/QAD.0b013e328360a4bd [doi]
PST - ppublish
SO  - AIDS. 2013 Jul 17;27(11):1707-16. doi: 10.1097/QAD.0b013e328360a4bd.